MedTrace Logo

A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients With Chronic Lymphocytic Leukaemia (CLL) Treated Within First-line Studies of the GCLLSG

NCT06792994 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2026-04-30

No results posted yet for this study

Summary

This observational trial is designed to investigate long-term survival with regard to the primary endpoint overall survival (OS) after start of first-line treatment.

Conditions

Interventions

OTHER

Observational

The data of this observational trial will be collected as part of routine patient care. Data relating to the time period between the end of participation in the clini-cal first-line trial (CLL13, CLL14, or CLL17) and inclusion in the observational trial will be documented retrospectively at the time point of inclusion in the observa-tional trial. From inclusion in the observational trial, data on survival, long-term efficacy, quality of life, and safety will be collected prospectively

Sponsors & Collaborators

  • GELLC (Grupo Español de Leucemia Linfocítica Crónica)

    collaborator OTHER

  • Nordic Lymphoma Group

    collaborator NETWORK

  • Polish Adult Leukemia Group

    collaborator OTHER

  • HOVON - Dutch Haemato-Oncology Association

    collaborator OTHER

  • German CLL Study Group

    lead OTHER

Principal Investigators

  • BArbara F. Eichhorst, MD · Uniklinik Köln

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-02
Primary Completion
2030-08-01
Completion
2030-08-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06792994 on ClinicalTrials.gov